Systemic therapy for advanced gastric cancer
Publication in refereed journal

Full Text

Times Cited

Other information
AbstractGastric cancer is the fourth commonest cancer worldwide, with nearly a million new patients being diagnosed with this disease per year, of whom 55% are in East Asia. Regrettably, despite the availability of potentially curative resection, between 50 and 90% of these patients die as a result of disease relapse. This article discusses systemic therapy for advanced gastric cancer, with a focus on cytotoxic chemotherapy and targeted therapy for unresectable, metastatic or recurrent disease. Older-generation cytotoxics entailed 5-fluorouracil, the platinum compound cisplatin, and anthracyclines (doxorubicin and epirubicin). In this disease setting, clinical trials have addressed the role of palliative chemotherapy versus best supportive care, as well as single agent versus combination chemotherapy. New cytotoxic agents that have been tested include oral fluoropyrimidines (capecitabine and S-1), other platinum derivatives (oxaliplatin), taxanes (docetaxel and paclitaxel) and irinotecan. Outcomes associated with various treatment regimens incorporating these newer agents and old-generation combination chemotherapy have been compared. The main biological agents that have been tested include those that act on 3 classes of molecular targets, namely human epidermal growth factor receptor 2, vascular endothelial growth factor, and epidermal growth factor receptor. © 2010 Hong Kong College of Radiologists.
All Author(s) ListYeo W.
Journal nameJournal- Hong Kong College of Radiologists
Detailed description13(Suppl).
Volume Number13
Issue Number3 SUPPL.
PublisherScientific Communications International Ltd.
Place of PublicationHong Kong
Pages25 - 28
LanguagesEnglish-United Kingdom
KeywordsAntineoplastic combined chemotherapy protocols, Neoplasm metastasis, Neoplasm recurrence, local, Stomach neoplasms, Treatment outcome

Last updated on 2021-22-10 at 23:36